# Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS

> **NCT00868166** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 512 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Olesoxime
- **DRUG:** Placebo Comparator
- **DRUG:** Riluzole

## Key facts

- **NCT ID:** NCT00868166
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-30
- **Primary completion:** 2011-09-30
- **Final completion:** 2011-09-30
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2020-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868166, "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00868166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*